

AVANIR PHARMACEUTICALS  
Form 8-K  
December 13, 2004

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

December 10, 2004

**Avanir Pharmaceuticals**

(Exact name of registrant as specified in its charter)

California

001-15803

33-0314804

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

11388 Sorrento Valley Road, San Diego,  
California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

858-622-5200

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 1.01. Entry into a Material Definitive Agreement.**

On December 10, 2004, Avanir Pharmaceuticals (the "Company") entered into a Stock Purchase Agreement with CDIB Capital Investment America Ltd., a wholly-owned subsidiary of China Development Industrial Bank Inc., pursuant to which the Company issued and sold 2,333,333 shares of Class A common stock at a price of \$3.00 per share, for aggregate offering proceeds of approximately \$7 million (the "Offering"). The Offering, which closed December 10, 2004, was made pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-114389).

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Avanir Pharmaceuticals

*December 10, 2004*

By: */s/ Gregory P. Hanson, CMA*

---

*Name: Gregory P. Hanson, CMA*

*Title: VP Finance & CFO*